Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

We recently developed a novel GLP-1 mimetics (supaglutide) by genetically engineering recombinant fusion protein production techniques. We demonstrated that this formulation possessed long-lasting GLP ...

Q4 2024 Earnings Call Transcript February 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to ...

Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

EFX is a fusion protein engineered to mimic FGF21 ... in spine and hip bone mineral density. For context, use of GLP-1 drugs for diabetes has been recently reported to be associated with about ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes ...

Nobody could have predicted the vogue for GLP-1 drugs to promote weight loss. In the US alone, the number of patients starting GLP-1 treatments for nondiabetic purposes has increased by 700% since ...

In this article, we are going to take a look at where Global Partners LP (NYSE:GLP) stands against other oil & gas stocks that are skyrocketing so far in 2025. The oil & gas sector has been quite ...

In this article, we are going to take a look at where Global Partners LP (NYSE:GLP) stands against other oil & gas stocks that are skyrocketing so far in 2025. The oil & gas sector has ...